## JBL: Jabil Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($215.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Can Sanmina's Thrust on 42Q Connected Manufacturing Boost Revenues?**
- Source: TradingView — Track All Markets | 20251229T160936 | Somewhat-Bullish | Relevance: 74%
- Sanmina Corporation is leveraging its 42Q connected manufacturing platform to integrate global factory and supplier data, enhancing visibility and decision-making for customers. This technology-driven approach, deployed in over 70 factories, aims to strengthen customer relationships and streamline manufacturing processes. Despite strong competition from Jabil and Celestica, Sanmina, with its "Strong Buy" Zacks Rank, shows promising growth in revenue and earnings estimates.

**2. Can Sanmina's Thrust on 42Q Connected Manufacturing Boost Revenues?**
- Source: Eastern Progress | 20251229T150910 | Somewhat-Bullish | Relevance: 72%
- Sanmina Corporation is heavily investing in its 42Q connected manufacturing system, which integrates data from customer factories and supplier fleets to create a unified, real-time information base. This technology aims to improve visibility, optimize production, reduce downtime, and enhance product quality for Sanmina and its customers. The company's focus on this technology and strong customer relationships is expected to drive revenue growth, positioning it strongly against competitors like Jabil and Celestica.

**3. UFP Technologies Is Growing Fast, Even If Its Stock Isn’t**
- Source: Finimize | 20251228T210905 | Neutral | Relevance: 65%
- UFP Technologies (UFPT), a specialist in medical device manufacturing, is expanding rapidly due to increased outsourcing demand and strategic acquisitions, yet its stock has underperformed, trading at a discount. Despite strong growth prospects, efficient capital use, and healthy cash flow, UFPT faces risks from customer concentration, regulatory hurdles, and potential margin pressures. The company presents a potentially attractive opportunity for long-term investors interested in medical device outsourcing, despite its recent stock performance.

**4. Apple Inc. $AAPL Stock Position Trimmed by WestHill Financial Advisors Inc.**
- Source: MarketBeat | 20251229T130246 | Neutral | Relevance: 64%
- WestHill Financial Advisors Inc. reduced its stake in Apple Inc. ($AAPL) by 4.9%, selling 2,156 shares to hold 41,971 shares valued at $10.687 million, making Apple its 10th largest holding. Concurrently, Apple CEO Tim Cook and SVP Deirdre O'Brien also sold significant amounts of company stock. Despite insider selling, large institutions like Vanguard and State Street increased their positions, and Apple reported strong quarterly EPS, while analysts maintain a "Moderate Buy" rating with an average target price of $283.92.

**5. Apple Inc. $AAPL Holdings Decreased by Generali Investments CEE investicni spolecnost a.s.**
- Source: MarketBeat | 20251229T100817 | Neutral | Relevance: 63%
- Generali Investments CEE investicni spolecnost a.s. reduced its holdings in Apple Inc. by 8.1% in the third quarter, while other institutional investors like Vanguard Group Inc. and State Street Corp increased their stakes. Company insiders sold shares totaling approximately $58.6 million in the last quarter. Analyst sentiment remains mixed-to-positive, with an average "Moderate Buy" rating and a target price of $283.92, supported by recent legal wins and new AI model releases despite concerns about Apple's position in generative AI.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $270 | $260 | +4% |
| 2025-12-18 | Barclays | $283 | $267 | +6% |
| 2025-12-18 | UBS | $244 | $239 | +2% |
| 2025-12-10 | B of A Securiti | $262 | $255 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-18 | Barclays | main | Overweight |
| 2025-12-18 | UBS | main | Neutral |
| 2025-12-10 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.00M) |
| Sells | 55 ($38.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.1%)
- Blackrock Inc.: 9.0% (+2.1%)
- Texas Yale Capital C: 6.0% (-0.1%)
- State Street Corpora: 4.9% (+0.7%)
- Wellington Managemen: 4.1% (-30.7%)

### Key Risks

1. Heavy insider selling: $39M sold (55 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +4%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 48%). Insider selling cluster ($38.9M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.7B |
| Beta | 1.26 |
| 52W Range | $108.66 - $237.14 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 17.1 |
| Current P/E | 19.9 |
| YoY Growth | 16.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.4% to 1.5% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.90), confirming momentum. RSI neutral at 60. OFD pattern: -FTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.47% (CS: 90) | Neutral |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 0.90 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.077x | Above |
| vs SMA200 | 1.189x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $231.72
- **Stop Loss:** $215.50 (7.0% risk)
- **Target:** $247.94 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $15,525.24
- **Portfolio %:** 15.53%
- **Risk Dollars:** $1,100.00
- **Risk Per Trade:** 1.10%
- **Modifiers:** L1 110% | L2 100% | Combined 1.10x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.73 | $2.85 | +4.4% |
| 2025Q3 | $2.95 | $3.29 | +11.7% |
| 2025Q2 | $2.32 | $2.55 | +9.8% |
| 2025Q1 | $1.83 | $1.94 | +6.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*